Media coverage about Intra-Cellular Therapies (NASDAQ:ITCI) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intra-Cellular Therapies earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.053390556796 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the news articles that may have effected Accern’s analysis:

Shares of Intra-Cellular Therapies (ITCI) traded up 2.23% on Friday, hitting $11.01. 225,935 shares of the stock were exchanged. The stock’s market cap is $478.10 million. The stock’s 50-day moving average is $11.97 and its 200-day moving average is $12.55. Intra-Cellular Therapies has a 1-year low of $7.85 and a 1-year high of $45.20.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.33. The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.03 million. Intra-Cellular Therapies had a negative net margin of 32,834.94% and a negative return on equity of 27.92%. The firm’s revenue for the quarter was down 52.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.71) earnings per share. Analysts forecast that Intra-Cellular Therapies will post ($2.65) earnings per share for the current year.

A number of research analysts recently weighed in on ITCI shares. Piper Jaffray Companies downgraded shares of Intra-Cellular Therapies from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $22.00 to $10.00 in a research report on Monday, May 1st. Ladenburg Thalmann Financial Services downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 2nd. BidaskClub downgraded shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Zacks Investment Research downgraded shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Tuesday, May 9th. Finally, Cantor Fitzgerald decreased their target price on shares of Intra-Cellular Therapies from $32.00 to $29.00 and set an “overweight” rating for the company in a research report on Tuesday, May 2nd. Two analysts have rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company. Intra-Cellular Therapies currently has an average rating of “Hold” and a consensus price target of $24.14.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Intra-Cellular Therapies (ITCI) Share Price” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.